Criteria for priority setting of HIV/AIDS interventions in Thailand: a discrete choice experiment Sitaporn Youngkong*1,2, Rob Baltussen*1, Sripen Tantivess*2, Xander Koolman*3 and Yot Teerawattananon*2 1 Nijmegen International Center for Health Systems Research and Education (NICHE), Department of

Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Waranya Rattanavipapong1, Tanunya Koopitakkajorn1, Naiyana Praditsitthikorn1,2,*, Surakameth Mahasirimongkol3 andYot Teerawattananon1 Summary Purpose There is strong evidence o

Abstract Objectives In Thailand, axillary lymph node dissection (ALND) is the dominant form of treatment for breast cancer, even though the treatment often leaves patients with some degree of arm morbidity. Sentinel lymph node biopsy (SNB) is widely accepted globally as a preferable alternative pr

Abstract Background: Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand. There have also been no economic evaluation studies of CHB drug treatments conducted in Thailand yet. I

Boonying Siribumrungwong1, Pinit Noorit2, Chumpon Wilasrusmee3, Pattara Leelahavarong4, Ammarin Thakkinstian5 and Yot Teerawattananon4 Abstract Objectives: To conduct economic evaluations of radiofrequency ablation, ultrasound-guided foam sclerotherapy and surgery for great saphenous vein ab

Objective: Implementing national-level vaccination programs involves long-term investment, which can be a significant financial burden, particularly in resource-limited settings. Although many studies have assessed the economic impacts of providing vaccinations, evidence on the positive and negative

Abstract BACKGROUND: Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis

Abstract BACKGROUND: Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis C v

Abstract India is at crossroads with a commitment by the government to universal health coverage (UHC), driving efficiency and tackling waste across the public healthcare sector. Health technology assessment (HTA) is an important policy reform that can assist policy-makers to tackle inequities an

ABSTRACT Objectives: This study aimed to analyse the cost–utility and budget impact of adding tocilizumab to the standard treatment for patients with refractory systemic juvenile idiopathic arthritis (sJIA) in Thailand. Design: Economic evaluation using a decision-analytical model. Setting: